A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Trial Profile

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs RP 6530 (Primary)
  • Indications T cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors Rhizen Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2016 Preliminary results (n=11) assessing safety and clinical activity, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 26 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top